Research progress of PCSK9 in the mechanism of atherosclerotic cardiovascular disease
10.3760/cma.j.cn431274-20221125-01230
- VernacularTitle:PCSK9在动脉粥样硬化性心血管疾病作用机制中的研究进展
- Author:
Yao ZHANG
1
;
Jinjing YANG
;
Jingyi LIU
;
Jingping WANG
Author Information
1. 山西医科大学，太原 030001
- Keywords:
Atherosclerosis;
Cardiovascular diseases;
PCSK9 inhibitors
- From:
Journal of Chinese Physician
2023;25(8):1260-1264
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitor has become a new drug for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease. Recent studies have shown that the mechanism of PCSK9 in atherosclerotic cardiovascular disease is very complex, which is closely related to the increase of plasma low-density lipoprotein cholesterol level, apoptosis, autophagy, inflammation, foam cell formation and vascular smooth muscle cell calcification, which will help us better understand the " multiple effects" of PCSK9 inhibitors. This review aims to analyze the research status of PCSK9 in molecular structure, cell function and cardiovascular disease treatment, which will further consolidate the success of new treatment strategies for atherosclerosis.
